Peptides DB
Research-centric peptide and protocol reference hub

NAD+ vs PE 22-28

Updated July 27, 2026 · Reviewed by the PeptidesDB Editorial team

NAD+: Research use — not FDA-approvedPE 22-28: Research use — not FDA-approved

A data-driven comparison of NAD+ and PE 22-28 (also searched as PE 22-28 vs NAD+) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

NAD+ centers on metabolic, while PE 22-28 leans toward metabolic. On indexed research, NAD+ is ahead (NAD+: 5 studies, Human evidence; PE 22-28: 5, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • NAD+ is strongest for metabolic; PE 22-28 for metabolic.
  • Evidence: NAD+ Human evidence (5 studies) vs PE 22-28 Human evidence (5).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

NAD+: Healing 3.0, Muscle 2.0, Metabolic 4.0, Neuro 3.0, Sleep 1.0, Immune 3.0, Skin 2.0 — PE 22-28: Healing 2.0, Muscle 0.0, Metabolic 4.0, Neuro 0.0, Sleep 0.0, Immune 3.0, Skin 0.0Healing & recovery — 3.0 / 5 · NAD+Muscle & body comp — 2.0 / 5 · NAD+Metabolic & appetite — 4.0 / 5 · NAD+Neuro & mood — 3.0 / 5 · NAD+Sleep & circadian — 1.0 / 5 · NAD+Inflammation & immune — 3.0 / 5 · NAD+Skin & aesthetics — 2.0 / 5 · NAD+Healing & recovery — 2.0 / 5 · PE 22-28Metabolic & appetite — 4.0 / 5 · PE 22-28Inflammation & immune — 3.0 / 5 · PE 22-28HealingMuscleMetabolicNeuroSleepImmuneSkin
NAD+PE 22-28

At a glance

NAD+Human evidence
Strongest: MetabolicStudies: 5Level:
PE 22-28Human evidence

TREK-1 Channel Blocker | Shortened Spadin Analog

Strongest: MetabolicStudies: 5Level: Emerging

NAD+ vs PE 22-28: side-by-side

MetricNAD+PE 22-28
ClassCognitive
Regulatory statusResearch use onlyResearch use only
Evidence gradeHuman evidenceHuman evidence
Studies indexed55
Research levelEmerging
Strongest effectMetabolic & appetiteMetabolic & appetite
Healing & recovery3.02.0
Muscle & body comp2.00.0
Metabolic & appetite4.04.0
Neuro & mood3.00.0
Sleep & circadian1.00.0
Inflammation & immune3.03.0
Skin & aesthetics2.00.0

▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).

Mechanism & pharmacokinetics

PropertyNAD+PE 22-28
MechanismElectron carrier in redox reactions

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is NAD+?

### Summary NAD+ (Nicotinamide adenine dinucleotide) is a crucial coenzyme involved in various metabolic processes, including energy production and cellular repair mechanisms. Recent research highlights its potential roles in protecting against oxidative stress and enhancing therapeutic efficacy in certain cancer treatments.

Full NAD+ profile, mechanism & studies →

What is PE 22-28?

### Summary PE 22-28 is a peptide that has garnered attention in various research contexts, particularly in relation to vascular health and metabolic conditions. Its potential implications in gestational diabetes and placental function are areas of ongoing investigation.

Full PE 22-28 profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingNAD+3.0/5 effect signal
MuscleNAD+2.0/5 effect signal
MetabolicEvenBoth ~4.0/5
NeuroNAD+3.0/5 effect signal
SleepNAD+1.0/5 effect signal
InflammationEvenBoth ~3.0/5
SkinNAD+2.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack NAD+ and PE 22-28?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

NAD+ vs PE 22-28: side effects

NAD+

No community-reported effects logged yet.

PE 22-28

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

NAD+ has 5 approved studies indexed (Human evidence), and PE 22-28 has 5 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is NAD+ or PE 22-28 better?

It depends on your goal. NAD+ is strongest for metabolic; PE 22-28 for metabolic. NAD+ has more indexed studies (5). See the goal-by-goal breakdown above.

Is NAD+ or PE 22-28 better for weight loss?

They score similarly on the metabolic/appetite axis in the community data.

Is NAD+ or PE 22-28 better for muscle?

NAD+ leads on the muscle & body-composition axis (2.0/5).

Which has more research, NAD+ or PE 22-28?

NAD+ has 5 approved studies indexed (Human evidence); PE 22-28 has 5 (Human evidence). Higher counts mean more to read, not proven superiority.

Can you stack NAD+ and PE 22-28?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of NAD+ vs PE 22-28?

NAD+: no community-reported effects logged yet. PE 22-28: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is NAD+ or PE 22-28 FDA-approved?

NAD+ is a research-use compound and is not FDA-approved. PE 22-28 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is PE 22-28 better than NAD+?

For metabolic, PE 22-28 has the edge; for metabolic, NAD+ does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

NAD+ and PE 22-28 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 27, 2026.